Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283478 · ClinicalTrials.gov registry record · NA
Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer
A NA study, sponsored by Kentuckiana Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00283478: Completed NA study, sponsored by Kentuckiana Cancer Institute.
NCT00283478 is a NA study that has completed, run by Kentuckiana Cancer Institute. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00283478, a NA study, has completed, sponsored by Kentuckiana Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.
Interventions
- DRUG Gemcitabine
- DRUG Iscar Quercus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-05 |
| Est. Completion | 2007-04 |
| Phase | NA |
What the finished NCT00283478 record still lists
NCT00283478 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00283478 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00283478 about?
NCT00283478 is a clinical study titled "Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer". To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.
What is the current status of trial NCT00283478?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2004-05. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00283478?
The interventions under investigation include: Gemcitabine (DRUG), Iscar Quercus (DRUG).
Who is sponsoring clinical trial NCT00283478?
This trial is sponsored by Kentuckiana Cancer Institute, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00283478's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia